Applications of H-D-Phe-Obzl P-Tosylate in Industrial Manufacturing

H-D-Phe-Obzl P-Tosylate is a key protected amino acid derivative widely applied in advanced organic synthesis and peptide manufacturing. Its stable structure and defined reactivity make it essential for various strict downstream sectors. As a direct manufacturer, we support application development across leading global industries with controlled quality and batch-to-batch consistency.

1. Pharmaceutical Peptide Synthesis

Major pharmaceutical companies use this protected amino acid in solid-phase peptide synthesis (SPPS) for active pharmaceutical ingredient (API) development. Its benzyl protection ensures selectivity in peptide bond formation, reducing racemization during coupling cycles. H-D-Phe-Obzl P-Tosylate is critical for manufacturing complex APIs for oncology, metabolic disorders, and rare disease therapeutics, particularly where phenylalanine residues impact bioactivity or receptor binding.

Industry compliance standards

• ICH Q7 Good Manufacturing Practice for Active Pharmaceutical Ingredients
• United States Pharmacopeia (USP) / European Pharmacopoeia (Ph. Eur.) guidelines for peptide APIs
• FDA 21 CFR Part 210/211 cGMP for finished pharmaceuticals
• EMA Guideline for the Manufacture of Sterile Medicinal Products

Typical usage ratio

• In peptide chain assembly, application ranges from 1.0 to 1.2 molar equivalents per coupling step, adjusted per resin loading and desired peptide sequence complexity.

Downstream process integration

• Charged during SPPS and liquid-phase peptide coupling after protecting group verification; deprotected post-assembly before purification and API crystallization.

Final product types

• Peptide active pharmaceutical ingredients (e.g., synthetic analogues of somatostatin, GnRH derivatives)
• Peptide-based injectable drugs
• Oral peptide tablets and capsules
• Peptide intermediates for further functional modifications

2. Diagnostic and Research Reagent Manufacturing

In in-vitro diagnostics (IVD) and bioreagent sectors, manufacturers employ this raw material for site-specific peptide labeling or synthesis of enzyme substrates carrying phenylalanine residues. The product’s defined purity supports demanding research applications, such as fluorescence resonance energy transfer (FRET) probe assembly and peptide arrays for high-throughput screening in pharmaceutical R&D.

Industry compliance standards

• ISO 13485:2016 Medical Devices – Quality Management System for IVD production
• ISO 9001:2015 for research reagent manufacturing
• REACH regulation for safe chemical handling
• Applicable OECD Good Laboratory Practice (GLP) for reagent validation

Typical usage ratio

• Typically 1.05 to 1.15 molar equivalents per chain elongation step in solid phase synthesis; optimization based on desired peptide length and resin efficiency.

Downstream process integration

• Included as a building block during stepwise assembly of diagnostic peptides or custom bioactive substrates; participates before conjugation or immobilization for microarray production.

Final product types

• Peptide probes for immunoassays
• Enzyme-linked immunosorbent assay (ELISA) standards
• Peptide microarrays for screening applications
• Labeled reference standards for research use

3. Biopharmaceutical Contract Manufacturing (CDMO/CMO)

Contract Development and Manufacturing Organizations scale the use of this phenylalanine derivative for client-specific peptide projects requiring cGMP compliance and full traceability. The material’s batch documentation and adherence to validated synthetic routes allow seamless technology transfer for pilot-to-commercial scale. It plays a core role for intermediates in oligopeptide platform drugs and biosimilar development.

Industry compliance standards

• FDA 21 CFR Part 820 for medical device and diagnostic components
• International Conference on Harmonisation (ICH) Q9 Quality Risk Management
• QSR and GMP for contract manufacturing of regulated substances
• Client-specific audit requirements and material traceability systems

Typical usage ratio

• Ranges from 0.95 to 1.10 equivalents per chain elongation, based on peptide complexity, scale (gram to kilogram), and client requirements.

Downstream process integration

• Introduced as a protected amino acid at validated step in large-scale solid-phase or solution-phase peptide synthesis; deprotection and purification aligned with batch QC protocols.

Final product types

• GMP-grade peptide intermediates
• Biologic development candidates for client submission
• Custom peptide therapeutics for human clinical trials
• Preclinical bioactive peptide samples

4. Custom Synthesis for Fine Chemical Intermediates

Specialty and fine chemical companies incorporate H-D-Phe-Obzl P-Tosylate during the multi-step synthesis of chiral building blocks and advanced intermediates required for fragrance ingredients, custom ligands, or alkaloid analogues. Its defined optical activity and reactive protection patterns permit selective transformations, supporting downstream enantioselective catalysis and functional group introduction for high-value fine chemicals.

Industry compliance standards

• REACH regulation for substance registration and safe handling
• ISO 9001:2015 for chemical process management
• Custom client quality specifications for chiral intermediates
• Audited supply chain traceability

Typical usage ratio

• Applied at 1.0–1.3 equivalents depending on the complexity of the target chiral center and presence of additional functional groups in downstream steps.

Downstream process integration

• Added during the early-stage synthesis or key coupling stages of custom intermediate manufacturing; participates before final deprotection or derivatization to yield enantiomerically pure components.

Final product types

• Protected chiral amino acid intermediates
• Advanced pharmaceutical or agrochemical precursors
• Chiral ligands for asymmetric catalysis
• High-purity specialty fine chemicals